Introduction
Obesity is defined as excess body fat by positive energy balance. It is associated with metabolic disease such as type 2 diabetes, hypertension, and coronary heart disease.
Obesity also increases the risk of several malignancies in breast, colon, pancreas, and endometrium. 1, 2 Menopause is a well-known risk factor for cardiovascular disease. During menopausal transition, women have a tendency to increase body weight. Consequently, menopause and the increase of body weight lead to an exponential increase of health risk for menopausal women. 3 To maintain healthy body weight, treatment of obesity in menopausal women is an important health issue.
Fundamental treatments of obesity include lifestyle intervention such as nutrition, physical activity, and behavior therapy. Pharmacotherapy can be used as an adjunct to lifestyle intervention. However, effects of lifestyle intervention are not always satisfactory in all cases.
Pharmacotherapy is used in many patients in conjunction with lifestyle intervention.
There are two groups of approved drugs that can be used to manage weight in patients with obesity: 1) medications approved for obesity per se; 2) medications that affect body weight for obese patients who have complications from their obesity and are receiving these medications for chronic disease management. 4 The second group of drugs is for patients with chronic disease such as diabetes, depression, or psychiatric disorders. These drugs have different effects on weight. The best choice is to select drugs that can produce weight loss. In the following sections, we will discuss the use of medications approved for obesity per se, including recently U.S. Food and Drug Administration (FDA) approved novel agents. or sleep apnea. 5 The flow of pharmacologic treatment for obesity is shown in Figure 1 . 5 For drugs approved for longterm use, if 3% mean weight loss is not achieved during 3 months of medication, there is a need to reconsider the treatment modality. Sibutramine, a highly selective inhibitor of reuptake of noradrenaline and serotonin at nerve endings, was the most frequently prescribed drug. However, after significantly more cardiovascular events were reported after using it compared to placebo group, it was withdrawn from the market. 6, 7 Drugs approved by U.S. FDA for obesity treatment are summarized in Table 1 . 
Orlistat (Xenical)
Orlistat is a potent and selective inhibitor of pancreatic lipase required for hydrolysis of dietary fat in gastrointestinal tract into fatty acids and monoacylglycerol. 9 It was approved by the U.S. FDA in 1999 as a long-term obesity management in conjunction with reduced-calorie diet.
Because orlistat is not absorbed to any significant degree, there is hardly any systemic reaction. 10 A 4-year doubleblind, randomized, placebo-controlled trial with orlistat in 3304 overweight patients revealed that 21% of patients with impaired glucose tolerance achieved mean weight loss more than 11% below baseline in the orlistat-treated group compared to 6% below baseline in the placebo-treated group during the first year of use. 11 Compared to lifestyle changes alone, orlistat plus lifestyle changes resulted in a greater reduction in the incidence of type 2 diabetes over 4 years.
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In addition, orlistat can improve cardiovascular risk factors.
Systolic and diastolic blood pressure, serum levels of total cholesterol, low-density lipoproteins (LDL)-cholesterol, and glucose were reported to be decreased in orlistat-treated group. 12 Orlistat can cause small but significant decreases in fat-soluble vitamins such as vitamin A, D, E, and K. shown pharmacologic effects on weight loss. 16 Fenfluramine and dexfenfluramine as serotonin type 2B receptor agonists were also used for weight loss. However, they were removed from market due to damage to heart valves through serotonin 2B receptor. 17 When serotonin-2C receptor is activated in the hypothalamus, food intake is reduced. 16 Lorcaserin is prescribed at 10 mg twice daily. Three (P < 0.001), and mean fasting glucose was decreased 27.4 ± 2.5 mg/dL compared to a decrease of 11.9 ± 2.5 mg/dL for placebo (P < 0.001; Fig. 2 ).
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Lorcaserin was carefully investigated for potential effects on heart valves during phase III studies where echocardiograms were done on more than 5200 subjects.
There was no statistically significant increase in FDAdefined valvulopathy with drug treatment as compared to placebo. 18~20 Therefore, U.S. FDA has not recommended routine echocardiography for prescription of this medication.
Lorcaserin is relatively well tolerated. The most common adverse events in clinical trials include headache, nausea, dizziness, fatigue, dry mouth, and constipation. These were mild that could be resolved quickly. Because of the risk of serotonin syndrome, it should not be used with selective serotonin reuptake inhibitors (SSRIs) or with monoamine oxidase inhibitors (MAOIs).
Phentermine/Topiramate Extended-release (ER) (Qsymia
® is the combination of phentermine and topiramate as an ER medication (Vivus Inc. Mountain View, CA, USA). As previous described, phentermine, a sympathomimetic drug, has been widely used as short-term appetite suppressant. Topiramate is an anticonvulsant drug.
Following anecdotal reports of weight loss occurring in patients with epilepsy, it was evaluated as a potential antiobesity drug in clinical trials. 21 In terms of mechanism of action, topiramate is not thoroughly understood, although it Basic treatment modalities of obesity include lifestyle intervention, pharmacotherapy, and bariatric surgery. In pharmacotherapy, many drugs have been withdrawn form market due to unacceptable side effects. In the past, only one medicine (orlistat) was available for long-term treatment of obesity. However, two novel agents were approved by U.S. FDA for long-term usage. Although further studies such as clinical outcome for longer period or for a specific age group are needed, it is obvious that the progression of pharmacotherapy for obesity treatment gives us chance to manage weight problem more effectively.
